Companies

Replimune Group, Inc. (REPL) SEC filings

CIK 0001737953 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 03/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2026FY2025FY2024FY2023
Net income (USD)-174.3 M-118.0 M
Diluted EPS (USD/shares)-3.38-3.24-2.99

Latest filings

FiledFormDescriptionPeriod
2026-09-168-KFORM 8-K items 5.03,5.07,9.012026-09-15
2026-08-244OWNERSHIP DOCUMENT2026-08-20
2026-08-194OWNERSHIP DOCUMENT2026-08-17
2026-08-14S-3ASRS-3ASR
2026-08-1410-Q10-Q2026-06-30
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-148-KFORM 8-K items 2.02,9.012026-08-14
2026-08-124OWNERSHIP DOCUMENT2026-08-10
2026-08-124OWNERSHIP DOCUMENT2026-08-10
2026-08-124OWNERSHIP DOCUMENT2026-08-10
2026-08-124OWNERSHIP DOCUMENT2026-08-10
2026-08-11SCHEDULE 13D/ASCHEDULE 13D/A
2026-08-11442026-08-11
2026-08-118-K/AFORM 8-K/A items 8.01,9.012026-08-09
2026-08-10SCHEDULE 13GSCHEDULE 13G
2026-08-108-KFORM 8-K items 8.01,9.012026-08-09
2026-08-10424B5424B5
2026-08-07SCHEDULE 13GSCHEDULE 13G
2026-08-078-KFORM 8-K items 8.01,9.012026-08-06
2026-08-06SCHEDULE 13G/ASCHEDULE 13G/A
2026-07-318-KFORM 8-K items 8.01,9.012026-07-30
2026-07-308-KFORM 8-K items 7.01,9.012026-07-30
2026-07-29EFFECTEFFECT items ,,
2026-07-29ARSARS2026-03-31
2026-07-29DEFA14ADEFA14A

Forms on file (last 1,000): 4 281, 8-K 110, SC 13G/A 37, 3 32, 10-Q 25, SC 13G 14, S-8 13, 424B5 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=REPL (0.002 USD), /gw/filings/filings?ticker=REPL&form=8-K, /gw/filings/facts?ticker=REPL&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange